Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Return on Equity: 2014-2025

Historic Return on Equity for Ocular Therapeutix (OCUL) over the last 11 years, with Sep 2025 value amounting to -0.88%.

  • Ocular Therapeutix's Return on Equity fell 50.00% to -0.88% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.88%, marking a year-over-year decrease of 50.00%. This contributed to the annual value of -0.81% for FY2024, which is 61.00% up from last year.
  • Per Ocular Therapeutix's latest filing, its Return on Equity stood at -0.88% for Q3 2025, which was down 12.46% from -0.78% recorded in Q2 2025.
  • Ocular Therapeutix's 5-year Return on Equity high stood at -0.30% for Q2 2024, and its period low was -16.05% during Q3 2023.
  • Moreover, its 3-year median value for Return on Equity was -0.78% (2025), whereas its average is -3.61%.
  • Data for Ocular Therapeutix's Return on Equity shows a peak YoY increase of 12,445bps (in 2021) and a maximum YoY decrease of 3,296bps (in 2021) over the last 5 years.
  • Ocular Therapeutix's Return on Equity (Quarterly) stood at -0.97% in 2021, then plummeted by 111bps to -2.08% in 2022, then increased by 27bps to -1.81% in 2023, then spiked by 132bps to -0.49% in 2024, then tumbled by 50bps to -0.88% in 2025.
  • Its Return on Equity stands at -0.88% for Q3 2025, versus -0.78% for Q2 2025 and -0.68% for Q1 2025.